G1 Therapeutics Stock Forecast, Price & News

G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

Is G1 Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than G1 Therapeutics?

Wall Street analysts have given G1 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but G1 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for G1 Therapeutics.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its earnings results on Wednesday, August, 4th. The company reported ($0.94) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.02. The firm had revenue of $6.60 million for the quarter, compared to the consensus estimate of $2.70 million. G1 Therapeutics had a negative net margin of 160.84% and a negative trailing twelve-month return on equity of 49.38%.
View G1 Therapeutics' earnings history.

How has G1 Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GTHX shares have increased by 5.7% and is now trading at $15.32.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for GTHX?

5 brokers have issued 12-month price objectives for G1 Therapeutics' stock. Their forecasts range from $21.00 to $82.00. On average, they expect G1 Therapeutics' share price to reach $53.00 in the next twelve months. This suggests a possible upside of 246.0% from the stock's current price.
View analysts' price targets for G1 Therapeutics or view top-rated stocks among Wall Street analysts.

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:

• Jack Bailey, President, Chief Executive Officer & Director
• Terry L. Murdock, Chief Operating Officer
• Jennifer K. Moses, Chief Financial Officer
• Rajesh K. Malik, Chief Medical Officer (LinkedIn Profile)
• David D. Elks, Head-Information Technology

Who are some of G1 Therapeutics' key competitors?

Some companies that are related to G1 Therapeutics include Pacira BioSciences (PCRX), Verve Therapeutics (VERV), Erasca (ERAS), Taro Pharmaceutical Industries (TARO), Cassava Sciences (SAVA), IGM Biosciences (IGMS), Atea Pharmaceuticals (AVIR), ATA (ATAI), Ligand Pharmaceuticals (LGND), Corcept Therapeutics (CORT), Morphic (MORF), Dynavax Technologies (DVAX), Harmony Biosciences (HRMY), Indivior (INVVY) and Myovant Sciences (MYOV).
View all of GTHX's competitors.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.63%), State Street Corp (6.54%), Vanguard Group Inc. (5.91%), JPMorgan Chase & Co. (4.43%), Dimensional Fund Advisors LP (2.53%) and Fisher Asset Management LLC (2.17%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, Mark A Velleca, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics.

Which major investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Susquehanna International Group LLP, Goldman Sachs Group Inc., MPM Oncology Impact Management LP, Burrage Capital Management LLC, PDT Partners LLC, Los Angeles Capital Management LLC, and Rafferty Asset Management LLC. Company insiders that have sold G1 Therapeutics company stock in the last year include Mark A Velleca, Rajesh Malik, and Seth Rudnick.
View insider buying and selling activity for G1 Therapeutics or view top insider-selling stocks.

Which major investors are buying G1 Therapeutics stock?

GTHX stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Morgan Stanley, Morgan Stanley, Point72 Asset Management L.P., Tekla Capital Management LLC, Dimensional Fund Advisors LP, Nuveen Asset Management LLC, and BlackRock Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $15.32.

How much money does G1 Therapeutics make?

G1 Therapeutics has a market capitalization of $648.77 million and generates $45.28 million in revenue each year. The company earns $-99,250,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis.

How many employees does G1 Therapeutics have?

G1 Therapeutics employs 122 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

Where are G1 Therapeutics' headquarters?

G1 Therapeutics is headquartered at 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at (919) 213-9835 or via email at [email protected].